The Prognostic Role of AmphirEgulin in the Treatment of Erlotinib Against Non-small Cell Lung Cancer with Wild-type EGFR
DING Jiang-hua
GONG Sheng-ping
WU Xiao-jian
XIE Lian-bin
Abstract：Objective To explore the prognostic role of amphiregulin (AREG) in the treatment of erlotinib against non-small cell lung cancer ( NSCLC) with wild-type epidermal growth factor receptor ( wt-EGFR) . Methods 40 consecutive patients with advanced NSCLC harboring wt-EGFR were collected in this study during Jan. 2010 and Jan. 2015 from the on-cology department of the 171st Hospital of PLA, the affiliated Hospital of Jiujiang University. The AREG expression was deter-mined by immunohistostaining with the aim of investigating the association between AREG level and the effect of erlotinib treat-ment. Results In the study, the patients with AREG-positive accounted for 65% (26/40), while 35% (14/40) patients were AREG-negative. The expression of AREG was correlated with the factor of age in patients (χ2 =4. 050, P=0. 0320). The overall response rate (OR) was 22. 5% (9/40) and the disease control rate (DCR) was 50. 0% (20/40) in the patients treated with erlotinib. The DCR in the AREG-positive group was markedly higher than that in the AREG-negative group (61. 5% vs 28. 6%, P =0. 0210). No significant difference was found in the OR between the two groups (26. 9% vs 14. 3%, P=0. 7800). The AREG-positive group achieved better prolonged progression-free survival (PFS) and overall sur-vival (OS) rates than that of the AREG-negative group (7 week vs 4 week, P =0. 0012; 11. 5 month vs 4 month, P =0. 0003). The incidence rate of skin rash in AREG-positive group was markedly higher than that in AREG-negative group (57. 7% vs 21. 4%, P=0. 0350) . Conclusion The advanced NSCLC patients harboring wt-EGFR with AREG-positive tumors may benefit from erlotinib treatment accompanying higher incidence rate of skin rash, indicating the potential molecular marker of AREG for the patients with wt-EGFR NSCLC when treated with erlotinib.
Keywords：AmphiregulinErlotinibCarcinomanon-small-cell lungPrognosis
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 66-70 )